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in an independent cohort demonstrating close association with relapse-
free and overall survival (5). 
Future comparative studies need to deﬁne “common” signatures from 
the different studies, which might optimize the gene prognostic models 
for early stage NSCLC.
DNA Synthesis and Repair genes (i. e RRM1 and ERCC1) have been 
associated with sensitivity to certain chemotherapeutica (gemcitabine/
cisplatinum). The prognostic value of these markers have also been 
studied by a new immunohistochemistry/ﬂuorescence technique (the 
AQUA-system), which demonstrated a strong association to survival 
after surgery for patients between high expression of RRM1 and 
ERCC1, especially for the 30% of the patients with tumors express-
ing both markers. As a single marker patients with high expression of 
RRM1 had an overall survival of 120 months versus 60 months for the 
patients with low expression (HR for death was 0.61, p=0.02). (6).
2. Advanced Disease: In the advanced disease situation the prognos-
tic information is more related to prediction of sensitivity to any give 
systemic therapy. Within the last years much progress has been done in 
this area, both with regard to new targeted therapies as well as conven-
tional chemotherapy.
Epidermal Growth Factor Tyrosine Kinase Inhibitors (EGFR TKIs) 
have demonstrated signiﬁcant effect in a subset of patients with ad-
vanced NSCLC. The identiﬁcation of certain EGFR mutations role for 
sensitivity to these agents was a signiﬁcant discovery and focused the 
future research in this ﬁeld (8). EGFR mutations in the tyrosine kinase 
domain, especially in exons 19 and 21 play a role for response to EGFR 
TKIs and several reports points to the fact that EGFR mutations in exon 
19 are more related to sensitivity than exon 21 mutations, which also 
seems to have a prognostic association (9). While the EGFR mutations 
in Asian populations seems to be clearly associated to survival as well, 
more clinical data seems to be needed to verify the same for the west-
ern populations. More consistent association to response and survival 
has been published for increased EGFR gene copy number detected by 
FISH (10, 11). While the routine use of tissue based predictive markers 
could have some limitations in terms of tissue acquisition and tumor 
heterogeneity, the identiﬁcation of blood- based predictive markers 
could be advantageous. Most recently, a serum proteomic proﬁling was 
identiﬁed, which could distinguish NSCLC patients with good and poor 
outcome after EGFR TKIs (12).
While other targeted therapies have emerged promising in the treatment 
of advanced NSCLC, no validated predictive molecular signatures have 
so far been identiﬁed, which could immediately be ready for routine 
clinical management.
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Appropriate management of (N)SCLC depends on precise disease 
staging and accurate response assessment. Currently, the tumor-node-
metastases (TMN) staging is used in most parts of the world. The 1997 
staging system adopted by the AJCC and UICC is currently undergoing 
revision as a result of the IASLC staging effort. 
In the recent years, common imaging modalities used for staging lung 
cancer patients include chest radiography, CT, magnetic resonance 
imaging, (FDG)PET and fused modality imaging (PET-CT). Whereas 
chest CT is useful in identifying tumor location and the presence of 
mediastinal lymph node involvement, its limitation is the ability to 
differentiate between benign and malignant pulmonary nodules and 
lymph nodes. FDG-PET as a single imaging modality has shown to be 
superior to conventional imaging in direct comparisons with respect 
to differentiate between benign and malignant pulmonary nodules, 
mediastinal lymph node metastases and distant metastatic disease (with 
the noteworthy exception of brain metastases). Although recent reports 
indicate that the accuracy of staging of integrated PET-CT is superior 
to either CT alone and dedicated PET that was visually correlated 
with a CT scan, the true cost-effectiveness of this staging modality 
is unknown. One drawback of FDG-PET is that it still lacks absolute 
speciﬁcity for differentiating benign (eg inﬂammation) from malignant 
disease. For this reason, tissue sampling of “decisive” lesions (eg those 
that will determine stage) is still mandatory. For suspect mediastinal de-
posits the procedure of choice has long been invasive surgical staging: 
depending on their localization either mediastinoscopy, mediastinoto-
my anterior or less frequently VATS. The advent of ultra sound (US) 
-guided endoscopes, through which ﬁne needle aspiration is possible, is 
now changing the diagnostic algorithm. Endobronchial US-guided ﬁne 
needle aspiration (EBUS) can be performed during ﬁberoptic bronchos-
copy, and a prior (PET-)CT allows nodes to be targeted and sampled, 
mainly in the same areas accessible to cervical mediastinoscopy, with 
the addition of some hilar nodes. Esophageal endoscopic ultrasound 
(EUS) allows examination of the posterior and inferior mediastinum 
and far more-the liver, the celiac axis, and the left adrenal gland. In 
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experienced hands, the positive predictive value for mediastinal lymph 
node involvement is in the order of 85%, thus in the same range as for 
mediastinoscopy. Several studies have shown that these techniques 
have the potential to prevent surgical procedures to a large extent (up to 
70%) and are cost-effective as compared to surgical staging. Thus, the 
initial staging algorithm of the not-too-distant future could include a 
contrast CT of the chest and upper abdomen, a PET-CT, brain imag-
ing (as clinically indicated), and an E(B)US FNA. Such an algorithm 
would also allow for mediastinoscopy to be used more freely as a 
restaging tool after induction therapies for locally advanced NSCLC 
when surgical treatment is considered. The need for a tissue diagnosis 
in this situation is more pressing as the accuracy of CT and PET-CT 
after induction therapies, especially when radiotherapy is involved, is 
unknown and most probably lower as for initial staging. 
Response assessment
Response to chemo(radio) therapy could be a surrogate for survival 
in non-small cell lung cancer (NSCLC), but it has become a contro-
versial measurement parameter because of the quantitative variability 
in measurement and the fact that differences in response rates are not 
commonly translated into differences in survival. This is not surpris-
ing indeed, as treatment responses with commonly employed methods 
(i.e CT, MRI) are still being assessed by measuring tumor sizes before 
and after treatment and classifying tumor shrinkage according to 
criteria that were developed more than 25 years ago. Part of the current 
excitement about molecular imaging with PET lies in its more practical 
manifestations: to provide noninvasive evaluation of tumour metabolic 
status, location, and response to therapy. PET has been a key technol-
ogy for these applications because its sensitivity allows the use of 
labeled probes at concentrations that do not perturb tumour metabolism 
or saturate molecular signatures that are up-regulated on tumour cells 
as a result of oncogenic transformation. 18FDG PET has the potential to 
improve upon existing methods to predict outcome in NSCLC. First, it 
has been shown that 18FDG uptake (SUV) in untreated NSCLC is close-
ly correlated with survival. A recent study conﬁrmed that 18FDG SUV 
has independent prognostic value in a cohort of 100 subsequent surgi-
cal NSCLC patients. Also, reproducibility of 18FDG uptake in untreated 
NSCLC is high, in most studies <15%. Second, residual 18FDG uptake 
several months after completion of treatment of patients with (locally) 
advanced NSCLC has been shown to correlate with histopathological 
response and predict survival more accurate as compared to CT based 
methods. Third, in the recent years it has become clear that metabolic 
response early in the course of treatment, i.e. after 1 cycle of chemo-
therapy, allows for prediction of subsequent reduction in tumor mass as 
well as patient survival . The latter may allow for early identiﬁcation of 
non responders which is of great clinical importance since the response 
rates of chemotherapy in advanced NSCLC are usually in the range of 
25%-35%. 
However, several questions remain. The best method and optimal 
timing to measure 18FDG response in NSCLC is not known and there 
is no general agreement what decrease in 18FDG uptake constitutes a 
metabolic response. This may especially of relevance when assessing 
the newer molecular therapies where a metabolic effect on non-cancer 
tissue cannot be excluded. Finally, as a tracer of metabolism, 18FDG is 
not a speciﬁc tumor marker. Other tracers, eg. 18FLT that reﬂect other 
tumor characteristics (proliferation), are explored with respect to their 
suitability to assess response to anticancer treatment. 
To date, there are no clinical studies available in the literature that 
compare standard therapy with “PET-controlled” therapy. Patients in 
the PET-controlled arm would receive 1 cycle of standard therapy after 
which metabolic non-responders would switch to alternative treatment, 
whereas metabolic responders would continue standard treatment. End-
points in such trials would be cost of treatment, treatment related toxic-
ity and survival . Randomised trials of this design are eagerly awaited.
PL3-01 Advances in Management of NSCLC, Thur, Sept 6, 08:15 - 10:00
Advances in Management of NSCLC - Advances in Chemotherapy
Johnson, David H. 
Hematology & Medical Oncology, Vanderbilt-Ingram Cancer Center, 
Nashville, TN, USA
Although reports of pulmonary malignancies date to antiquity, lung 
cancer is largely a disease of modern man (1, 2). Prior to 1900, lung 
cancers were viewed as “matters of medical curiosity not known to 
be in any degree inﬂuenced by medicine and too rare to be of much 
practical importance” (2). By the mid-20th century, however, lung 
cancer had become epidemic and ﬁrmly established as a leading cause 
of cancer-related death throughout much of the industrialized and de-
veloping world (3). For much of the 20th century the systemic treatment 
of advanced NSCLC was considered completely inadequate (4, 5). In 
fact, as recently as 1998 the noted oncologist B.J. Kennedy derisively 
commented on the “snail’s pace” of progress in the management of late 
stage NSCLC (6). Fortunately, much has changed since Dr. Kennedy’s 
scholarly rebuke. It is now well established that modern chemotherapy 
can prolong survival of NSCLC patients with late stage disease as well 
as improve the symptoms and quality of life in a cost effective manner 
(5, 7, 8). Although no single chemotherapy regimen stands apart as 
optimal treatment for all patients with advanced NSCLC, most experts 
agree that doublet platinum-based chemotherapy with a 3rd generation 
drug is the preferred treatment for physically ﬁt patients (7-9). Contro-
versy persists vis-à-vis the superiority of cisplatin versus carboplatin in 
the ﬁrst-line setting (10). Nonetheless, non-platinum therapy is a rea-
sonable alternative approach in selected circumstances where cisplatin 
or carboplatin is not appropriate. Subtle differences among the extant 
regimens allow clinicians ﬂexibility to choose among toxicity pro-
ﬁles, convenience, and cost (11, 12). For a subset of NSCLC patients, 
namely those with adenocarcinoma, no CNS metastases or hemoptysis, 
the addition of bevacizumab to chemotherapy is warranted based on a 
signiﬁcant improvement in overall survival (13). Whether the addition 
of bevacizumab to chemotherapy doublets other than carboplatin and 
paclitaxel proves beneﬁcial remains to be determined although initial 
reports are encouraging in this regard (14). The available data indicate 
that no more than three to six cycles of chemotherapy are required to 
achieve optimal survival results and minimize host toxicity (15, 16). 
Second line chemotherapy is clearly beneﬁcial in terms of survival, 
quality of life and cost (17). The choice of 2nd-line therapy is dictated 
largely by the toxicity proﬁles of the available drugs (18). Older pa-
tients who are physically ﬁt should be treated in a manner that mirrors 
that of their younger counterparts (19, 20). Older patients who are not 
physically ﬁt and patients with a poor initial performance status may 
be candidates for monotherapy with a 3rd generation cytotoxic drug 
or possibly one of the newer so-called targeted agents (e.g. erlotinib) 
(21). On a precautionary note, however, at least one small trial suggests 
chemotherapy may be superior to selected targeted agents in this setting 
(22). By contrast, EGFR tyrosine kinase inhibitors appear active as 
initial therapy for patients over the age of 70 years (23). A prospective 
comparative trial with chemotherapy is warranted. Physicians may one 
day employ biomarkers to select appropriate therapy for individual 
patients. Recent advances in molecular biology and proteomic research 
